Info: Read More
  • 中药标准品生产商,产品定制服务
  • 多烯紫杉醇;多西他赛

    Docetaxel

    多烯紫杉醇;多西他赛
    产品编号 CFN98517
    CAS编号 114977-28-5
    分子式 = 分子量 C43H53NO14 = 807.88
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Diterpenoids
    植物来源 The barks of Taxus chinensis (Pilger) Rehd.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    多烯紫杉醇;多西他赛 CFN98517 114977-28-5 10mg QQ客服:2056216494
    多烯紫杉醇;多西他赛 CFN98517 114977-28-5 20mg QQ客服:2056216494
    多烯紫杉醇;多西他赛 CFN98517 114977-28-5 50mg QQ客服:2056216494
    多烯紫杉醇;多西他赛 CFN98517 114977-28-5 100mg QQ客服:2056216494
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • University of Padjajaran (Indonesia)
  • Johannes Gutenberg University Mainz (JGU) (Germany)
  • Kazusa DNA Research Institute (Japan)
  • Sanford Burnham Prebys Medical Discovery Institute (USA)
  • Max Rubner-Institut (MRI) (Germany)
  • Michigan State University (USA)
  • University of Wuerzburg (Germany)
  • Universita' Degli Studi Di Cagliari (Italy)
  • Universitas islam negeri Jakarta (Indonesia)
  • Chulalongkorn University (Thailand)
  • University of Queensland (Australia)
  • Universitas Airlangga (Indonesia)
  • University of Cincinnati (USA)
  • Medical University of South Carolina (USA)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Analytical Letters.2020, doi 10.1008
  • Cells.2023, 12(1):168.
  • South African J of Plant&Soil2018, 29-32
  • J Sep Sci.2022, 45(18):3556-3566.
  • Kor. J. Pharmacogn.2016, 47(1):62-72
  • J Ethnopharmacol.2019, 235:406-414
  • Front Pharmacol.2022, 13:972825.
  • Biochem Biophys Res Commun.2018, 505(4):1148-1153
  • Korean J. Medicinal Crop Sci.2018, 26(2):148-156
  • Agronomy2023, 13(6), 1435.
  • Sci Rep.2018, 8:15059
  • Chin J Appl. Physiol.2019, 35(3):283-288
  • Phytomedicine.2017, 24:77-86
  • Anal Bioanal Chem.2018, 410(5):1561-1569
  • Drug Dev Res.2020, doi: 10.1002
  • Cell Death Dis.2019, 10(12):882
  • Journal of Life Science2017, 233-240
  • J Nat Prod.2019, 82(4):1002-1008
  • Biochem Biophys Res Commun.2021, 534:802-807.
  • Cells.2021, 10(10):2633.
  • Molecules.2022, 27(22):7997.
  • Journal of Applied Pharmaceutical Science2022, 0(00), pp:001-007
  • Nat Commun.2021, 12(1):681.
  • ...
  • 生物活性
    Description: Docetaxel is an antineoplastic drug by inhibiting microtubule depolymerization, and attenuating of the effects of bcl-2 and bcl-xL gene expression.
    Targets: VEGFR | Bcl-2 | Bcl-xL
    In vitro:
    Cancer Treat Rev. 2015 Mar;41(3):262-70.
    Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.[Pubmed: 25683304]
    Paclitaxel and docetaxel represent the most adopted taxanes in the neoadjuvant treatment of HER2-positive breast cancer. Questions still remain with regard to their difference in terms of activity and tolerability.
    METHODS AND RESULTS:
    Events for pathological complete response (pCR), severe and febrile neutropenia (FN), and severe neurotoxicity were pooled by adopting a fixed- and random-effect model. A sensitivity analysis to test for the interaction between paclitaxel and docetaxel was accomplished. Absolute differences with 95% confidence intervals (CIs) and the number of patients needed to treat/harm (NNT/NNH) were calculated to derive the Likelihood of being Helped or Harmed (LHH). Data from 15 trials (3601 patients) were included. Paclitaxel significantly increases pCR rate by 6.8% in comparison with docetaxel (43.4%, 95% CI 41.1-45.7% versus 36.6%, 95% CI 34.3-39.0%, p=0.0001), regardless of the chemotherapy backbone, with an absolute difference of 9% and 9.2% for anthracycline-based or free-regimens. Paclitaxel significantly improves pCR versus docetaxel with a single HER2-inhibition by 6.7% (p=0.0012), with no difference if combined with a dual HER2-inhibition. Severe neutropenia and FN are significantly lower with paclitaxel, with an absolute difference of 32.4% (p<0.0001) and 2.5% (p=0.0059), respectively. Conversely, severe neurotoxicity is slightly higher with paclitaxel (3%, p=0.0001). The LHH ratio calculated for pCR and severe neutropenia is 2.0 and 0.7 for paclitaxel and docetaxel.
    CONCLUSIONS:
    Although the activity of neoadjuvant paclitaxel and docetaxel HER2-positive breast cancer is considered similar, the slight advantage in pCR, the significantly lower neutropenia and FN, do favor paclitaxel (in the weekly fashion) over docetaxel, despite the slightly worst neurotoxicity.
    In vivo:
    BJU Int. 2015 May;115(5):744-52.
    Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.[Pubmed: 24947139]
    To evaluate the benefit of Docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer (mCRPC) relapsing after an initial good response to first-line Docetaxel.
    METHODS AND RESULTS:
    We retrospectively reviewed the records of consecutive patients with mCRPC with a good response to first-line Docetaxel [serum prostate specific antigen (PSA) decrease ≥50%; no clinical/radiological progression]. We analysed the impact of management at relapse (Docetaxel rechallenge or non-taxane-based therapy) on PSA response, symptomatic response (performance status/pain/analgesic consumption), and overall survival (OS). We used multivariate stepwise logistic regression to analyse potential predictors of a favourable outcome. We identified 270 good responders to first-line Docetaxel. The median progression-free interval (PFI) was 6 months from the last Docetaxel dose. At relapse, 223 patients were rechallenged with Docetaxel (82.5%) and 47 received non-taxane-based therapy. There was no significant difference in median OS {18.2 [95% confidence interval (CI) 16.1-22.00] and 16.8 [95%CI 13.4-21.5] months, respectively, P = 0.35}. However, good PSA response and symptom relief/stable disease were more frequent on Docetaxel rechallenge (40.4% vs 10.6%, P < 0.001 for PSA). A PFI of >6 months and added estramustine predicted a good PSA response and symptomatic response on Docetaxel rechallenge but only a PFI of >6 months predicted longer OS. Haemoglobin (<13 g/dL) and pain were associated with reduced OS. Docetaxel rechallenge increased the incidence of grade ≥3 sensory neuropathy, nail disorders and asthenia/fatigue.
    CONCLUSIONS:
    Docetaxel rechallenge is a management option for responders to Docetaxel with a PFI of >6 months, but did not prolong survival. Potential benefits should be weighed against the risk of cumulative toxicity.
    N Engl J Med. 2004 Oct 7;351(15):1513-20.
    Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.[Pubmed: 15470214]
    Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer.
    METHODS AND RESULTS:
    We compared Docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer. Of 674 eligible patients, 338 were assigned to receive Docetaxel and estramustine and 336 to receive mitoxantrone and prednisone. In an intention-to-treat analysis, the median overall survival was longer in the group given Docetaxel and estramustine than in the group given mitoxantrone and prednisone (17.5 months vs. 15.6 months, P=0.02 by the log-rank test), and the corresponding hazard ratio for death was 0.80 (95 percent confidence interval, 0.67 to 0.97). The median time to progression was 6.3 months in the group given Docetaxel and estramustine and 3.2 months in the group given mitoxantrone and prednisone (P<0.001 by the log-rank test). PSA declines of at least 50 percent occurred in 50 percent and 27 percent of patients, respectively (P<0.001), and objective tumor responses were observed in 17 percent and 11 percent of patients with bidimensionally measurable disease, respectively (P=0.30). Grade 3 or 4 neutropenic fevers (P=0.01), nausea and vomiting (P<0.001), and cardiovascular events (P=0.001) were more common among patients receiving Docetaxel and estramustine than among those receiving mitoxantrone and prednisone. Pain relief was similar in both groups.
    CONCLUSIONS:
    The improvement in median survival of nearly two months with Docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 1.2378 mL 6.189 mL 12.3781 mL 24.7562 mL 30.9452 mL
    5 mM 0.2476 mL 1.2378 mL 2.4756 mL 4.9512 mL 6.189 mL
    10 mM 0.1238 mL 0.6189 mL 1.2378 mL 2.4756 mL 3.0945 mL
    50 mM 0.0248 mL 0.1238 mL 0.2476 mL 0.4951 mL 0.6189 mL
    100 mM 0.0124 mL 0.0619 mL 0.1238 mL 0.2476 mL 0.3095 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    7-Xylosyltaxol B; 7-Xylosyltaxol B CFN89398 90352-19-5 C50H61NO18 = 964.01 5mg QQ客服:215959384
    Taxcultine; Taxcultine CFN96640 153415-46-4 C44H53NO14 = 819.90 5mg QQ客服:3257982914
    N-Methyltaxol C ; N-Methyltaxol C CFN89043 153083-53-5 C47H59NO14 = 861.97 5mg QQ客服:1457312923
    紫杉醇 C ; Taxol C CFN96633 153415-45-3 C46H57NO14 = 847.95 5mg QQ客服:215959384
    7-木糖基-10-去乙酰基紫杉醇 C; 7-Xylosyl-10-deacetyltaxol C CFN89385 90332-65-3 C49H63NO17 = 938.02 20mg QQ客服:1413575084
    13-O-Cinnamoylbaccatin III ; 13-O-Cinnamoylbaccatin III CFN89044 220932-65-0 C40H44O12 = 716.77 5mg QQ客服:215959384
    卡巴他赛中间体; Cabazitaxel intermediate CFN89140 1354900-65-4 C51H59NO15 = 926.02 5mg QQ客服:2159513211
    多烯紫杉醇;多西他赛; Docetaxel CFN98517 114977-28-5 C43H53NO14 = 807.88 20mg QQ客服:3257982914
    10-乙酰多西他赛; N-Debenzoyl-N-(tert-butoxycarbonyl)taxol CFN98516 125354-16-7 C45H55NO15 = 849.92 5mg QQ客服:215959384
    三尖杉宁碱; Cephalomannine CFN98518 71610-00-9 C45H53NO14 = 831.91 20mg QQ客服:1457312923

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产